Arbutus Biopharma Corp (ABUS)

The Nasdaq is one of the top three most-followed stock market indices in the United States, comprising over 2,500 stocks.

Jim Cramer, the host of Mad Money, offered his insights into the market's recent performance, highlighting why the tech-heavy Nasdaq failed to make a strong rebound.

Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript November 6, 2024Arbutus Biopharma Corporation reports earnings inline with expectations.

Inflation in the U.S. has dropped to the lowest level since 2021, setting the stage for the Federal Reserve to cut interest rates.

Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 Second Quarter Financial Results and Corporate Update. [Operator Instructions].

Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1.

Arbutus Biopharma Corporation reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12.

Operator: Good day, and thank you for standing by. Welcome to the Arbutus Third Quarter Corporate and Financial Update Conference Call.